online strategy meeting 2020€¦ · world to share ideas, challenges and lessons learned....

PROVENTAI N T E R N A T I O N A L

AGENDA ONCOLOGY

TRACK 2 - ONCOLOGY PRECISION MEDICINE / PERSONALISED MEDICINE

TRACK 1 - ONCOLOGYBIOMARKER DISCOVERY

TRACK 4 - ONCOLOGY ANTIBODY DISCOVERY

TRACK 3 - ONCOLOGY COMPANION DIAGNOSTICS

TRACK 6 - ONCOLOGYCLINICAL RESEARCH

TRACK 5 - ONCOLOGY IMMUNO-ONCOLOGY / CHECK POINT INHIBITORS

TRACK 8 - BIOINFORMATICS TRANSLATIONAL MEDICINE & INFORMATICS

TRACK 7 - BIOINFORMATICS GENOMICS

TRACK 10 - BIOINFORMATICS DATA INTEGRATION / DATA MINING

TRACK 9 - BIOINFORMATICS ARTIFICIAL INTELLIGENCE / MACHINE LEARNING

TRACK 12 - BIOINFORMATICSBIG DATA / DATA MANAGEMENT

TRACK 11 - BIOINFORMATICS DATA VISUALISATION

AGENDA BIOINFORMATICS

2019 ATTENDEES

SPONSORS

Click here to find out what our clients think about our Strategy Meetings

Fred Jacobs CEO TYG Oncology

Suzanne Saffie-Siebert CEO SiSaf

Alvaro Costa CEO Alkol Biotech

Soren Bregenholt CEO Macrophage Pharma

Paul Agapow Director Health Informatics AstraZeneca

Wolfgang Hackl Founder OncoGenomX

Steven Zimmer CEO EPICOMBI Therapeutics

Philip Beer Director Tessellex Ltd.

Marcelo Garcia Former Head of Medical SystemNovartis

Geert C. Mudde Founder and CSO TYG oncology Ltd

STANSTED

CONTRIBUTORS TO THE AGENDAOUR UNIQUE ONLINE MEETING FORMAT

Roundtable DiscussionsThese interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

Personalised AgendaEach delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent on the online platform is focused and well-utilised.

One-to-one MeetingsThe most effective and time efficient way to assess potential partners at a strategic level. Gain access to our exclusive networking app to identify the people that you need to meet. The app will allow for instant anddirect messaging to organise online meetings during the dedicated time to most benefit you.

Strategic NetworkingStrategic networking opportunities form a key benefit of the meeting. Our new online format for building and strengthening alliances to make lasting connections that benefit you.

http://

2020JUNESTRATEGY 30thONLINE MEETING

https://proventainternational.com/testimonials/

http://www.facebook.com/proventainternational

http://www.linkedin.com/company/5027394

http://twitter.com/proventaintl

https://proventainternational.com/


1

CO-HOST

GO TO MENU NEXT PAGEPREVIOUS PAGE

ONTOFORCE empowers data-driven decisions, drives innovation and speeds up cycle time. We unlock and connect siloed data into a linked data fabric. This enables everyone to securely integrate, analyse, and extract data faster, bringing simplicity to complexity. With DISQOVER, ONTOFORCE developed an innovative, self-service, linked data platform that delivers trusted and timely insights for end users.

VISIT WEBSITE

BioLizard is an expert team of data and bio-engineers dedicated to developing solutions for scientific research using bioinformatics, biostatistics, ML and AI. BioLizard transforms scientific data into highly valuable information, providing the necessary solutions to the most pressing questions. Our specialty is gathering a range of expertise tailored-made to our customers’ needs and developing innovative bioinformatics solutions required for even the most complex biological datasets. We implement up-to-date technological tools to assist our customers with their biological data integration, algorithm development, bioinformatics analyses, and pipeline implementation and automation. Importantly, our professionals are also familiar with specific life science expertise.VISIT WEBSITE

PRO-PARTNERS

VISIT WEBSITE VISIT WEBSITEVISIT WEBSITE VISIT WEBSITE VISIT WEBSITE VISIT WEBSITE VISIT WEBSITE

VISIT WEBSITE

Inteliquet is a leading provider of technology, insights and expertise for clinical research, patient treatment, and translational medicine strategies. Our proprietary platform securely, accurately, and quickly aggregates and analyzes healthcare data, helping to ensure clinical trials are designed more effectively, patients are matched to trials more rapidly and patient-care decisions are made using real-world evidence. Our team is passionate about ensuring every patient — regardless of race, geography, age, sex, economic status, or stage of disease — has access to promising therapies as soon as they become available to help improve the care they receive.

VISIT WEBSITE

tics delivers a ready-to-use platform to capture, register, share, collaborate, query, visualise and analyse all the information and knowledge generated in the modern, highly collaborative scientific industries. tics has significant expertise in scientific informatics, including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration, screening data management, SAR analysis, reporting, and visualisation. The enterprise solutions are flexible, scalable and configurable, providing effective scientific information management across entire organisations, from discovery research to development and early manufacturing. VISIT WEBSITE

At Proventa Talent, we always look ahead to ensure that the service we deliver to you is second to none, both now and in the future. Proventa Talent based around our three key principles of commitment, intelligence and partnership ensures an unparalleled recruitment solution in the industry. We work with the leading talent in the field to offer a service of high quality, efficiency and transparency. In addition to this, our relationship with many organisations across the Life Sciences sector means that we are constantly developing our recruitment services to offer market-leading solutions including Contingency, Executive Search, Contract and fully integrated Recruitment Process Outsourcing to suit your short, medium and long term needs.

VISIT WEBSITE

Sygnature Discovery is a leading integrated drug discovery and pre-clinical services company. We operate fully equipped modern research facilities in Nottingham and Alderley Park, UK, housing over 300 research scientists (>80% with PhDs). Our experienced drug hunters possess all the professional skills and know-how to enable success in the most demanding of research programmes and drive them from target validation through hit identification, hit-to-lead and lead optimisation to pre-clinical development candidate. Since 2011, we have delivered 31 drug candidates to our clients, 15 of which have subsequently entered the clinic (Phases I, II and III). To find out more about us, visit our website: www.sygnaturediscovery.com

VISIT WEBSITE

LeapAnalysis (LA) is a state-of-the art search and analytics engine and the first ever to offer virtualized connectivity to any data source directly. It allows for true federation of enterprise data. LA utilizes metadata and machine learning to understand your data sources. Sophisticated translators then operate directly on sources natively. Data can remain in siloes, while behaving as though it were in a common location. Leverage the power of your data from a single user perspective and begin your path to Al.

VISIT WEBSITE

BC Platforms is a world leader providing powerful genomic data management and analysis solutions to address some of the biggest healthcare challenges today by leveraging the convergence of genomics and healthcare information technologies. Our high performing genomic data management platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. BC Platforms’ vision is to revolutionize decision making in drug development to bring clinical benefits to patients. With twenty years of experience, BC Platforms truly is an expert in understanding the science of life.

VISIT WEBSITE

Contextual Genomics makes high-quality cancer genomic information accessible and affordable with our clinically-validated assays, informatics, and support. Our suite of genomics-based cancer tests is clinically actionable and cost-effective, designed to advance cancer prevention, treatment, and monitoring. Founded and led by global experts in oncology and bioinformatics, and with support from pharmaceutical and diagnostic partners, we are leading the shift towards precision cancer care.

VISIT WEBSITE

At PerkinElmer Informatics, our focus is on redefining how labs in Pharma, Biotech, Chemicals and major academic centers embrace electronic data capture, cloud-based applications and collaborative tools to manage and analyze their data. With our cloud based collaboration solutions and powerful visual analytics platforms, critical scientific data transforms into actionable insights in an automated, predictive and scalable way. Our solutions include the industry leading ChemDraw application, robust ELN, advanced analytics powered by TIBCO® Spotfire and the Signals Platform. The cloud based PerkinElmer SignalsTM platform unlocks the hidden knowledge within your scientific data whether you are working independently or collaboratively with solutions for Translational Medicine, Screening, Lead Discovery, and Biologics.

VISIT WEBSITE

ENPICOM is an innovative bioinformatics software engineering company with an outstanding team of over 25 professionals. They focus on supporting immunotherapy developers with groundbreaking products and customized solutions to improve and accelerate the discovery and development of novel immunotherapies. Clinical validation projects to stratify patients and monitor treatment responses to immunotherapies under development are ongoing. Leveraging a unique mix of biological knowledge, bioinformatics method development, and software engineering skills, ENPICOM developed a world-class repertoire sequencing data analysis solution, the ImmunoGenomiX (IGX) platform. IGX is an innovative platform to manage, store, analyze, visualize, and interpret immune repertoire sequencing data from T and B cell receptors.

SPONSORS

https://www.ontoforce.com/

http://lizard.bio

https://www.iddi.com/

https://www.nagarro.com/en

http://www.criteriuminc.com

https://www.accugenomics.com/

https://aws.amazon.com/

https://www.accenture.com/ph-en

https://www.wuxiapptec.com/

https://inteliquet.com/

https://www.dotmatics.com/

https://proventainternational.com/talent-acquisition/

www.sygnaturediscovery.com

https://www.leapanalysis.com/

https://www.bcplatforms.com/

https://contextualgenomics.com/

https://www.perkinelmer.com/

https://enpicom.com/


2 GO TO MENU NEXT PAGEPREVIOUS PAGE

ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR



ROUND TABLE TOPIC CONFIRMED FOR SPONSOR


Biomarker discovery and validation: genomics

and beyond

Machine learning informed biomarker selection using multi-omics integration.

Extracellular RNA biomarkers for Oncology - Advantages &

Disadvantages

01 02 03 04 05 06

Precision Oncology - the road ahead from “vaguely right” to “precisely right”

Gaining value from initial clinical data in personalised medicine FIH studies

Precision Medicine the Way Forward

Improve treatment efficacy and reduce patients side effects, through the optimization of

companion diagnosis

Invent new R&D partnership models to accelerate adoption of

companion diagnostics

How do you optimize CDx assays before you have access to stratified

clinical samples?

Antibody engineering considerations for immuno-oncology

ADC’s: Current challanges and opportuinities

Investments for PoC antibody discovery

Disciplined alliance management as a facilitator of successful global

discovery collaborations

How the Immuno-Oncology Therapies Have Changed the Standard of Care in Oncology

Discovery of ImmunoOncology Therapies: Antibody and Virus-based Approaches

BIOMARKER DISCOVERY PRECISION MEDICINE PERSONALISED MEDICINE COMPANION DIAGNOSTICS ANTIBODY DISCOVERY IMMUNO-ONCOLOGY

CHECK POINT INHIBITORS

Wolfgang Hackl - FounderOncoGenomX

David Huntsman - CMO & Brady Davis - SVP Peter B. Malamis - SVP, Life ScienceLorenzo Fanchi – Product Manager

Lore Gruenbaum - Vice President The Leukemia & Lymphoma

SocietyFatima Ann Sulaiman - Head of Resrc.

Scleroderma and Raynaud’s UKZahra Jawad - Group Leader

AgenusSoren Bregenholt - CEO

Macrophage Pharma

Achim Kless - Pain Gen. Lead Eli Lilly and Company Ltd

Lucy Clossick Thomson - DirectorArchilles Therapeutics

Henry Alistair - Head of Discov. Science UCB

Geert C. Mudde - Founder and CSO TYG oncology Ltd

Om P. Sharma, MS, PhD - Senior Dir. Daiichy-Sanyko

CLINICAL RESEARCH

Title TBC

Antibody Drug Conjugates (ADC) in Cancer Therapy

Real time Trials: Genomics & small target population

Aleksandra Filipovic - Therapeutic Lead PureTech Health

Prasun Mishra, Ph.D.- Founder and CEO Agility Pharma, MetaImmune Inc. and

American Association for Precision Medicine

12:00 - 12:30

19:20 - 20:20

14:30 - 15:30

18:00 - 19:00

13:30 - 14:30

19:00 - 19:20

12:30 - 13:30

15:30 - 17:30

17:30 - 18:00

TIME ( *B.S.T. )TRACK & ROOM

7:00 - 7:30

14:20 - 15:20

9:30 - 10:30

13:00 - 14:00

8:30 - 9:30

14:00 - 14:20

7:30 - 8:30

10:30 - 12:30

12:30 - 13:00

TIME ( *E.T. )TRACK & ROOM

NETWORKING BREAK1 - 1 MEETING *13:30-13:50 B.S.T. NETWORKING BREAK

1 - 1 MEETING *19:00-19:20 B.S.T.

1 - 1 MEETING *13:50-14:10 B.S.T. 1 - 1 MEETING *14:10-14:30 B.S.T.

1 - 1 MEETING *15:30-15:50 B.S.T. 1 - 1 MEETING *16:10-16:30 B.S.T. 1 - 1 MEETING *16:50-17:10 B.S.T.1 - 1 MEETING *15:50-16:10 B.S.T. 1 - 1 MEETING *16:30-16:50 B.S.T. 1 - 1 MEETING *17:10-17:30 B.S.T.

KEYNOTE PRESENTATION Current personalised medicine strategies provide limited clinical benefit – how do we do better?

Dr Allan Jordan - Director of Oncology Drug Discovery - Sygnature Discovery

KEYNOTE PRESENTATION Enabling Translational Oncology data integration, management & analysis for multidimensional Biomarkers discovery & Patients stratification

Eduardo Gonzalez-Couto - Translational Medicine Product Manager - PerkinElmer Informatics

AGENDA



07 08 09 10 11 12



ROUND TABLE TOPIC CONFIRMED FOR SPONSOR



How to Improving Drug Development and Clinical trials with Real World

Evidence

The World’s Most Dangerous Hormone

Improving the efficiency of Clinical trials with real world data

Tackling Complexity in drug discovery: single targets or multiple

ones?

Foundational concepts for good design thinking, intelligent adaption

and community adoption

AI in drug discovery: challenges and opportunities

Using data analytics to drive innovation and value

The importance of data integration in Clinical Trials; accessibility to data set for reproducibility and

study expansion

Data integration solution, for the improvement of research

How do we gain mechanistic insights from multi-level data

integration?

Integration, Analysis & Visualisation of Biological Data

Making better informed decisions from visualisation and analytic tools

ML for real world: How can big data bring the future of AI into medicine

Big Data for the development of new crop varieties for the biobased markets

Breaking down barriers to AI adoption in health care

TRANSLATIONAL MEDICINE & INFORMATICS AI & MACHINE LEARNING DATA INTEGRATION &

DATA MINING DATA VISUALISATION BIG DATA & DATA MANAGEMENT

Paul Agapow - Health Info. Director AstraZeneca

Steven Zimmer - CEO EPICOMBI Therapeutics Ltd.

Emma Laing - Lead Bioinform. Eli Lilly

Fred Jacobs - CEOTYG-Oncology

David Hamilton - Associate Director Novartis

Alvaro Costa - CEOAlkol Bioteck

Chris Penkett - Head of Pipelines Univ. of Cambridge

Tim Van den Bulcke - Head Bioinfo. Galapagos

Marcelo Garcia - Former HeadNovartis

GENOMICS

Design & execution of optimal cross-platform translational medicine programmes to

define in-human mechanism of action and identify

therapeutic biomarkers.Philip Beer - Director

Tessellex Ltd.

Bio-Courier Technology as Non-Viral Delivery System for

Gene Therapy.

Suzanne Saffie-Siebert - CEO SiSaf

The Evolving Landscape of Compute for Genomics

Charles Bradshaw - Head of Bioinf. The Gurdon Institute

12:00 - 12:30

19:20 - 20:20

14:30 - 15:30

18:00 - 19:00

13:30 - 14:30

19:00 - 19:20

12:30 - 13:30

15:30 - 17:30

17:30 - 18:00

TIME ( *B.S.T. )TRACK & ROOM

7:00 - 7:30

14:20 - 15:20

9:30 - 10:30

13:00 - 14:00

8:30 - 9:30

14:00 - 14:20

7:30 - 8:30

10:30 - 12:30

12:30 - 13:00

TIME ( *E.T. )TRACK & ROOM

NETWORKING BREAK1 - 1 MEETING *13:30-13:50 B.S.T. NETWORKING BREAK

1 - 1 MEETING *19:00-19:20 B.S.T.

1 - 1 MEETING *13:50-14:10 B.S.T. 1 - 1 MEETING *14:10-14:30 B.S.T.

1 - 1 MEETING *15:30-15:50 B.S.T. 1 - 1 MEETING *16:10-16:30 B.S.T. 1 - 1 MEETING *16:50-17:10 B.S.T.1 - 1 MEETING *15:50-16:10 B.S.T. 1 - 1 MEETING *16:30-16:50 B.S.T. 1 - 1 MEETING *17:10-17:30 B.S.T.

Hans Constandt - FounderTom Oldfield - Principal Software Archt. Jennifer Cubino - EVP & Umesh Katpally - Dir.Wim Van Criekinge - Co-founder Eric Little, PhD - CEO & Co-Founder

KEYNOTE PRESENTATION Current personalised medicine strategies provide limited clinical benefit – how do we do better?

Dr Allan Jordan - Director of Oncology Drug Discovery - Sygnature Discovery

KEYNOTE PRESENTATION Enabling Translational Oncology data integration, management & analysis for multidimensional Biomarkers discovery & Patients stratification

Eduardo Gonzalez-Couto - Translational Medicine Product Manager - PerkinElmer Informatics

AGENDA



LEARN MORE ABOUT OUR SPEAKERS

Eduardo Gonzalez-Couto Translational Medicine

Product Manager PerkinElmer Informatics

MORNING KEYNOTE

TIME SLOT (*B.S.T.)

Enabling Translational Oncology data integration, management & analysis

for multidimensional Biomarkers discovery & Patients stratification

• In translational oncology, predictive and prognostic quantitative biomarkers have been associated to increasingly larger data sets, growing in complexity and diversity • Agile informatics solutions are required to empower translational scientists to rapidly explore and analyze composite translational datasets • PerkinElmer Signals™ Translational empowers domain experts through Spotfire, a rich visual environment, connected to the Cloud

12:00 - 12:30

Dr Allan Jordan Director of Oncology

Drug Discovery Sygnature Discovery

AFTERNOON KEYNOTE

TIME SLOT (*B.S.T.)

Current personalised medicine strategies provide limited clinical

benefit – how do we do better?• What is the current clinical landscape for personalised medicines and targeted therapeutics?• How do we make significant impacts on overall survival?• How do we deliver benefit to patients with no known drivers?• Where will the next generation of therapeutics come from?

17:30 - 18:00

KEYNOTEPRESENTATION

http://proventainternational.com/events/rd/online/oncology-bioinformatics-online/


5

Lore Gruenbaum Vice President of the Therapy

Acceleration Program Leukemia & Lymphoma

Society

Biomarker discovery and validation: genomics and beyond

• Key technologies driving innovation• Impact on translational strategies and clinical studies• Challenges & Outlook: maximizing value generation from ‘big data’”

Achim Kless PhDPain Genetics Lead, Discovery

Neuroscience Research, Neuroscience Genetics

Eli Lilly and Company Ltd

Machine learning informed biomarker selection using multi-omics integration.

SPEAKER TBC TBC TBC

Biomarkers in Diagnosis: challenges and approaches.

Extracellular RNA biomarkers for Oncology - Advantages &

Disadvantages

SPEAKER TBC TBC TBC

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20

SPONSOR ROUNDTABLE TOPIC



TRACK 1 BIOMARKER DISCOVERY



6

Brady Davis, MBASenior Vice President, Business Development Contextual Genomics

Wolfgang HacklFounder & CEO OncoGenomX

Precision Oncology - the road ahead from “vaguely right” to

“precisely right”.

Lucy Clossick Thomson Director of Clinical

OperationsAchilles Therapeutics

Gaining value from initial clinical data in personalised medicine FIH studies

• Handling large volumes of data in a short amount of time• But not reduced SDV• Working with clinical trial centres in cell therapy

Precision Medicine the Way Forward• The present status of precision medicine• Unlocking the promise of precision medicine• Scaling precision medicine, challenges and opportunitiesPrasun Mishra, Ph.D.

Founder and CEO Agility Pharma, MetaImmune Inc.

and American Association for Precision Medicine



ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20

Liquid Biopsy: Is it changing the practice of precision oncology?

TIME SLOT (*B.S.T.)14:30 - 15:30


• When is a liquid biopsy most appropriate?• How is the pandemic changing demand for liquid biopsy?• Educating providers, payors, and patients

Dr. David Huntsman, MD, FRCPC, FCCMG Chief Medical Officer Contextual Genomics

TRACK 2 PRECISION MEDICINE / PERSONALISED MEDICINE



7

TRACK 3 COMPANION DIAGNOSTICS

Fatima Ann SulaimanHead of Research & Services Scleroderma & Raynaud’s UK

Improve treatment efficacy and reduce patients side effects, through

the optimization of companion diagnosis.

SPEAKER TBC TBC TBC

Invent new R&D partnership models to accelerate adoption of companion

diagnostics.

SPEAKER TBC TBC TBC

Multiplex companion diagnostics –development to commercialisation.

How do you optimize CDx assays before you have access to stratified

clinical samples?SPEAKER TBC

TBC TBC



TIME SLOT (*B.S.T.)

ROUNDTABLE TOPIC

12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20




8

TRACK 4 ANTIBODY DISCOVERY

Antibody engineering considerations for immuno-oncology

Henry AlistairHead of Discovery Science

UCB

Zahra JawadGroup Leader in

Discovery TechnologyAgenus

ADC’s: Current challanges and opportuinities

SPEAKER TBC TBC TBC

Engineering Better Antibody Therapeutics Using Computational

Approaches.

Investments for PoC antibody discovery.

SPEAKER TBC TBC TBC



ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20




9

TRACK 5 IMMUNO-ONCOLOGY / CHECK POINT INHIBITORS

Soren BregenholtCEO

Macrophage Pharma

Disciplined alliance management as a facilitator of successful global

discovery collaborations.

Geert C. Mudde Founder and CSO TYG oncology Ltd

How the Immuno-Oncology Therapies Have Changed the Standard of Care in OncologyIT started with tumour specific treatment (e.g. Herceptin) and but now addresses the immune system itself (e.g. Opdivo).• Is this still affordable if treatment prices are above €200K?• How do patients cope with the autoimmune side effects?• How do patients cope with the uncertainty of clinical efficacy in the absence of biomarkers?• The search for biomarkers has led to an explosion of clinical trials… Are there any patients left?

Lorenzo Fanchi Product Manager

ENPICOM

Discovery of ImmunoOncology Therapies: Antibody and Virus-based

Approaches.• Novel model of accelerating drug development in IO: from target identification to clinic in 4 years• Important consideration for next generation IO targets and therapies• Making sure that the patient features throughout the drug development process

Aleksandra FilipovicTherapeutic Lead for

Oncology PureTech Health



ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20

SPONSOR ROUNDTABLE TOPICMaximize your immune repertoire sequencing

data output with an end-to-end platform• How it is possible to sequence B or T cell receptors, also referred to as an immune repertoire, to collect a wealth of information about immune responses?• How can repertoire sequencing data effectively be applied to accelerate drug discovery and development of immunotherapies?• How can you manage, analyze, and visualize repertoire sequencing data even without bioinformatics skills?



10

TRACK 6 CLINICAL RESEARCH

Topic TBC

Om P. Sharma, MS, PhD Senior Director

Global Oncology R&D Daiichy-Sanyko

Antibody Drug Conjugates (ADC) in Cancer Therapy

• Make up of an ADC• Linker technology• Mechanism of action• How ADCs work in cancer therapy?• Limited systemic exposure hence less toxicity• Higher tumor selectivity• Targeted cancer cell killing• Recent market approval of ADCc• Future of ADCs”

Peter B. Malamis SVP, Life Science

Inteliquet

Using EMR RWE to Improve Clinical Research and Patient Enrollment

Real time Trials: Genomics and small target

population.SPEAKER TBC

TBC TBC

SPEAKER TBC TBC TBC



ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20


• Solving the Patient Data Challenge• Case Study: Precision Feasibility Assessment and Projections• Evidence-based Bioinformatics via High-quality Data



11

TRACK 7 GENOMICS

Philip BeerDirector

Tessellex Ltd.

Design and execution of optimal cross-platform translational medicine programmes to define in-human mechanism of action and identify

therapeutic biomarkers.• How can we best use genomic profiling to expedite drug discovery, drug development and clinical trial enrolment?• What are the most suitable technology platforms and assay designs to facilitate the above?• Can we afford this? How can we keep costs manageable?• What are the best mechanisms for drug developers and healthcare providers to collaborate in the genomic profiling of oncology patients?• How do we federate information to create big data?

Charles BradshawHead of Bioinformatics Core

The Gurdon InstituteUniversity of Cambridge

What can pharmaceutical R&D executives do to successfully lead

human genetics enabled R&D organizations?

Prof. Wim Van CriekingeCo-founder BioLizard

Next generation biomarkers: from omics to precision medicine

Bio-Courier Technology as Non-Viral Delivery System for Gene Therapy.

Suzanne Saffie-Siebert CEO

SiSaf Ltd.



ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20


• From candidate gene to genome-wide profiling• Integration of bioinformatics and database-driven approaches• Importance of machine learning in biomarker discovery cycle



12

TRACK 8 TRANSLATIONAL MEDICINE & INFORMATICS

Paul Agapow Health Informatics Director

AstraZeneca

How to Improving Drug Development and Clinical trials with Real World Evidence

• Clinical trials and drug development in general are getting more expensive to the point of no return• RWE has been suggested as a way to save money and speed development, e.g. synthetic control arms, using for precision medicine• However widespread use of RWE is hindered by data quality, data size, patient complexity• What has to be done to enable RWE?”

Fred Jacobs CEO

TYG-Oncology

The World’s Most Dangerous Hormone

Eric Little, PhD Chief Data Officer

OSTHUS; CEO & Co-Founder

LeapAnalysis

Improving the efficiency of Clinical trials with real world data.

• Storage and access to raw data• Access to data from failed trials so duplication of research can be minimised• How to ensure all information is registered responsibly through the duration of a trial”

Chris Penkett Head of Pipelines NHSBTUniversity of Cambridge



ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20

SPONSOR ROUNDTABLE TOPICAccelerating Your Translational Medicine with

Virtualized Semantics & FAIR Data• Why is Translational Medicine so hard to accomplish from a data integration perspective?• How metadata can help in understanding the important context of Translational Medicine data.• Analytics requires users are able to find and utilize high-quality data, but data is often disconnected, in incompatible formats and inconsistently labeled.• Driving data and analysis to a wide variety of users, using a wide range of applications, is key to servicing different researchers with different needs and perspectives.



13

TRACK 9 ARTIFICIAL INTELLIGENCE / MACHINE LEARNING

Steven Zimmer CEO

EPICOMBI Therapeutics Ltd.

Tackling Complexity in drug discovery: single targets or multiple ones?

David Hamilton Associate Director, Clinical Development & Analytics

Novartis

Foundational concepts for good design thinking, intelligent adaption and

community adoption• Good Design Thinking: What is it and where do we go wrong?• From Concept to Creation: How to focus open concepts and ideas into MVPs• The When that Wins: All In, Buy In• Essentials for Community Adoption - Overcoming Obstacles• The Four Phases of Adoption

Tom Oldfield Principal Software

Architect Dotmatics

AI in drug discovery: challenges and opportunities.

Tim Van den BulckeHead of Bioinformatics

Galapagos



What does AI mean in Bioinformatics

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20


• What existing ML tools have delivered results in Bioinformatics?• Can the bench biologist trust the results of ML?• When does knowledge discovery become deep learning?



14

TRACK 10 DATA INTEGRATION / DATA MINING

Using data analytics to drive innovation and value

The importance of data integration in Clinical Trials; accessibility to data

set for reproducibility and study expansion.

Hans ConstandtFounder

Ontoforce

Shift from application thinking to data thinking

Data integration solution, for the improvement of research.



ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20


• How can technology help to automate data curation and integration?• Where are we with semantics, linked data and FAIR data at work in data ecosystems?• UX as an unrecognized need for FAIR data?• Requirements to create a metadata and data catalog for research and clinical data?

SPEAKER TBC TBC TBC

SPEAKER TBC TBC TBC

SPEAKER TBC TBC TBC



15

TRACK 11 DATA VISUALISATION

Emma Laing Lead Bioinformatician

Eli Lilly

Bioimaging data analysis in disease diagnosis and data visualization in

large-scale biodata.

Integration, Analysis and Visualisation of Biological Data.

SPEAKER TBC TBC TBC

How visualisation and analysis tools can better support R&D decision

making.

Making better informed decisions from visualisation and analytic tools.

SPEAKER TBC TBC TBC

SPEAKER TBC TBC TBC



ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

TIME SLOT (*B.S.T.)14:30 - 15:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20




16

TRACK 12 BIG DATA / DATA MANAGEMENT

SPEAKER TBC TBC TBC

M-L for real world: How can big data bring the future of AI into medicine.

Alvaro Costa CEO

Alkol Biotech

Big Data for the development of new crop varieties for the biobased

markets.

Breaking down barriers to AI adoption in health care.

• Brainstorm challenges of AI adoption in healthcare• Group the identified challenges in some significant way• Discuss possible approaches to address the identified challenges• Pick up one/several conclusion(s) from the discussion to understand the takeaways

Marcelo Garcia Former Medical Systems Head

Novartis



ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)12:30 - 13:30

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)18:00 - 19:00

ROUNDTABLE TOPIC

TIME SLOT (*B.S.T.)19:20 - 20:20

Umesh Katpally Ph.D. Director, Data Advisory for Data Sciences BC Platforms

Maximizing the value of Real World Data

TIME SLOT (*B.S.T.)14:30 - 15:30


• Evaluations for how to secure access to diverse, comprehensive and representative data sets• Considerations for enterprise software architecture - data integration, harmonization, storage and analytics• How to maximize the access of data across silos and with appropriate controls and governance

Jennifer Cubino, MA, CCRA EVP, Head of Data Science BC Platforms



17

2019 ATTENDEES p.1


COMPANYABPIAIT Austrian Institute of Technology GmbHAlkol BiotechAmgenAmgenAmgenArtios PharmaAstraZenecaAstraZenecaAstraZenecaAstraZenecaAstraZenecaAstraZenecaAstraZenecaAstraZenecaBar Ilan UniversityBayer AGBiogenBiogenBiomedical Research Centre at Guy’s Hospital and King’s College LondonBiozentrum, University of BaselBluebird bioBlueprint MedicinesBoehringer Ingelheim Bridge Biotec LtdBrunel University LondonC4x DiscoveryC4x Discovery Coordination Centre for Clinical Trials (KKS)Debiopharm InternationalE Therapeutics PLCEli LillyEli LillyErasmus MCeTherapeuticsFraunhofer ITEM GalapagosGenomics EnglandGlaxoSmithKlineGlaxoSmithKline

JOB TITLE

Head of Health Data & OutcomesThematic CoordinatorCEOEuropean RWD leadProgramming Lead for Europe, Centre for Observational ResearchDirectorPrincipal Scientist, BioinformaticsGlobal Head of Health InformaticsHealth Informatics DirectorPrincipal ScientistPrincipal Data ScientistSenior Director, Knowledge ManagementAssociate Director, BioinformaticsAssociate Principal Informatics ScientistProgramme Manager, Clinical Information SharingProfessor/Director Clinical Development LeadHead of Computational ChemistryMedical Director, EU & Canada Medical Strategy & Execution LeadHead of Genomics Research Platform and Single Cell Facility and Senior Research FellowHead Research ITAssociate Director Medical AffairsInternational Head of Precision MedicineClinical Program LeadDirector / CEOSenior LecturerTarget Discovery Genetics Project LeaderVP Novel Target Biology & GenomicsDirectorVP Translational MedicineBusiness Development and Programme DirectorLead Senior BioinformaticianSenior BioinformaticianProfessorPrincipal Data ScientistGroup LeaderHead of BioinformaticsHead of Bioinformatics PartnershipsGlobal Head Computational Biology and Stats Scientific Leader

Glenmark PharmaceuticalsGoldsmiths, University of LondonGrünenthalGSKGSKGSKGSKGSKHiFiBioImmatics BiotechImperial College LondonImperial College LondonInflaRx InflaRxIO BiotechiOnctura SA IpsenIpsenJanssenJuno Therapeutics, a Celgene companyKarus TherapeuticsKing’s College LondonKymabLeo PharmaLondon South Bank UniversityMax Planck Institute for Biology of AgeingMedigene Immunotherapies GmbHMedImmuneMerckMerck KGaAMerck KGaAMerck KGaAMerck KGaAMerck Sharp & DohmeMerusMolecular Partners, AGMorphoSysMorphoSysNanna Therapeutics

Senior Vice President, Global Head of Translational SciencesProfessor of Cognitive ComputingScientific Director Senior Scientific DirectorSenior MetaData ManagerInterim Head of Human Genetics Computational BiologySenior MetaData ExpertScience Advisor Gene Therapy and Rare DiseaseEVP Business DevelopmentDirector, Clinical DevelopmentResearch FellowProfessor/ Director CISBIOCMOProgram Director Clinical Research & Development OncologyChief Medical OfficerChief Operating OfficerVice President Translational Sciences & Clinical Pharmacology Medical DirectorMedical Manager OncologySenior Vice President and Managing DirectorChief Operating Officer and Chief Scientific OfficerDirector of eResearchSenior Scientist (KY1005 Scientific Lead) , Transnational MedicinePrincipal ScientistProfessor, Head of Big Data and Informatics Research GroupHead of BioinformaticsDirectorVP Clinical RespiratoryDirector Cancer & Inflammation, Scientific Site Head Immuno-OncologyDirector Oncology BioinformaticsMarket Access Lead Oncology EMEADirector, Clinical Quality ManagementSenior Director, Head Biomarker Development & Validation StrategyDirector, R&D Analytics Executive Vice President and Chief Scientific OfficerVP, Head of Immuno-oncologyDirector, Program LeaderVice President & Head of CommercialDirector of Informatics

COMPANY JOB TITLE


18

2019 ATTENDEES p.2

GO TO MENUPREVIOUS PAGE

COMPANY

Nektar TherapeuticsNeovii Pharmaceuticals NovartisNovartis“Novartis “NovozymesOncoOneOncoQR MLOxford BioTherapeuticsOxford BioTherapeuticsPhilochemPierisPierre FabreProthenaQueen Mary UniversityRocheRocheRocheRocheRoche Roche Roche DiagnosticsRoche PharmaSandoz International

JOB TITLE

Vice President and Head of DiscoveryChief Scientific OfficerData Science Head MusculoskeletalHead of Medical Affairs OREMedical Systems Head - ICE, Global Medical AffairsHead of IT DepartmentCEOChief Scientific Officer and Managing DirectorDirector of Information Systems and BioinformaticsChief Executive OfficerGlobal Head of Precision MedicineDirector Immuno OncologyVice President – Head of Translational MedicineEU Medical Affairs headProfessor and Director, Centre for Translational Bioinformatics Global Head Strategic Alliances PREDiHead of Global BI Solution Center WelwynDigital Lead for Large Molecule ResearchDirector External Innovation, Oncology DiscoveryGlobal Medical DirectorGlobal Studies LeaderHead Data ManagementSenior LeaderHead Strategy and Novartis Collaborations

Sanofi

SanofiServierServierServier Deutschland GmbH ShireTakedaThemis BiosciencesTYG OncologyUCBUCBUCBUCLUniversität zu Lübeck, Medical Systems BiologyUniversity College LondonUniversity of BaselUniversity of BuckinghamUniversity of CambridgeUniversity of Halle-WittenbergUniversity of Leipzig University of LübeckUniversity of MunichUniversity of PlymouthVertex Pharmaceuticals

Sr Director, European Head of Medical Affairs for Oncology, Hematology and Solid Organ TransplantationMedical Manager Oncology GSAHead of Bioinformatics and Computational BiologyHead of Global Oncology Early Products StrategyDirector BU Oncology / HematologyGlobal Medical LeadScientific Informatics ArchitectHead ImmunotherapyChief Executive Officer and Co-Founder Director, Translational Bioinformatics, NeurosciencesHead of IT, New Medicines Innovation Senior Data Acquisition ManagerAcademic Lead of UCL GenomicsGroup LeaderProfessor of Bioinformatics and Computational BiologyProject HeadInterim Dean – School of ComputingHead of Bioinformatics CoreGroup LeaderDeputy HeadProfessor for Systems MedicinePrivate ProfessorProfessor in BioinformaticsDirector, Scientific Computing

COMPANY JOB TITLE

online strategy meeting 2020€¦ · world to share ideas, challenges and lessons learned....

Documents